tert-butyl N-[4-chloro-3-(hydroxymethyl)phenyl]carbamate | 200214-48-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl N-[4-chloro-3-(hydroxymethyl)phenyl]carbamate
• 英文别名: tert-butyl (4-chloro-3-(hydroxymethyl)phenyl)carbamate；1,1-dimethylethyl [4-chloro-3-(hydroxymethyl)phenyl]carbamate；2-chloro-5-(Boc-amino)benzyl alcohol
• CAS: 200214-48-8
• 化学式: C₁₂H₁₆ClNO₃
• 分子量: 257.717
• InChiKey: QELHOZLOTUGMOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[4-chloro-3-(hydroxymethyl)phenyl]carbamate 在 盐酸 、 18-冠醚-6 、 硫酸 、 四丁基氟化铵 、 potassium carbonate 、 N,N-二异丙基乙胺 、 potassium iodide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 生成 2-(5-tert-butoxycarbonylamino-2-chloro-phenyl)-acrylic acid ethyl ester
  参考文献：
  名称：

  3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa)

  摘要：

  A novel series of cyclic potent, selective, small molecule, thiol-based inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa) and the crystal structures of TAFIa inhibitors bound to porcine pancreatic carboxypeptidase B are described. Three series of cyclic arginine and lysine mimetic inhibitors vary significantly in their selectivity against other human basic carboxypeptidases, carboxypeptidase N and carboxypeptidase B. (-)2a displays TAFIa IC50 = 3 nM and 600-fold selectivity against CPN. Inhibition of TAFIa with (rac)2a resulted in dose dependent acceleration of human plasma clot lysis in vitro and was efficacious as an adjunct to tPA in an in vivo rabbit jugular vein thrombolysis model.

  DOI：

  10.1016/j.bmcl.2006.11.078
• 作为产物：
  描述：

  2-氯-5-硝基苯甲醛 在 sodium tetrahydroborate 、 铁粉 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 tert-butyl N-[4-chloro-3-(hydroxymethyl)phenyl]carbamate
  参考文献：
  名称：

  New Hits as Antagonists of GPR103 Identified by HTS

  摘要：

  Preclinical data indicate that GPR103 receptor and its endogenous neuropeptides QRFP26 and QRFP43 are involved in appetite regulation. A high throughput screening (HTS) for small molecule GPR103 antagonists was performed with the clinical goal to target weight management by modulation of appetite. A high hit rate from the HTS and initial low confirmation with respect to functional versus affinity data challenged us to revise the established screening cascade. To secure high quality data while increasing throughput, the binding assay was optimized on quality to run at single concentration. This strategy enabled evaluation of a larger fraction of chemical clusters and singletons delivering 17 new compound classes for GPR103 antagonism. Representative compounds from three clusters are presented. One of the identified clusters was further investigated, and an initial structure activity relationship study is reported. The most potent compound identified had a pIC(50) of 7.9 with an improved ligand lipophilic efficiency.

  DOI：

  10.1021/ml400519h

文献信息

• (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS
  申请人：Ballell Pages Lluis

  公开号：US20120095064A1

  公开（公告）日：2012-04-19

  A compound of Formula (I) wherein: either X is N and Y is CR 5 or X is C and Y is S; Z is selected from N and CH; R 1 is selected from H and Me; R 2 is selected from H, OH, OMe and Me; each R 3 is independently selected from C 1-3 alkyl, F, Cl, Br, CF 3 and NH 2 ; R 4 is selected from Me, CF 3 , NO 2 and CHF 2 ; R 5 is selected from H, Me and CHF 2 ; R 6 is selected from H and Me; and p is 0-3, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

  一个由Formula (I)组成的化合物 其中：X为N且Y为CR5，或者X为C且Y为S；Z从N和CH中选择；R1从H和Me中选择；R2从H、OH、OMe和Me中选择；每个R3独立地从C1-3烷基、F、Cl、Br、CF3和NH2中选择；R4从Me、 、NO2和CHF2中选择；R5从H、Me和 中选择；R6从H和Me中选择；p为0-3，提供了含有它们的组合物，它们在治疗中的使用，例如在结核病治疗中的使用，以及制备这类化合物的方法。
• [EN] BENZOTHIOPHENE SULFONAMIDES AND OTHER COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN<br/>[FR] BENZOTHIOPHÈNE SULFONAMIDES ET AUTRES COMPOSÉS QUI INTERAGISSENT AVEC UNE PROTÉINE RÉGULATRICE DE LA GLUCOKINASE
  申请人：AMGEN INC

  公开号：WO2013173382A1

  公开（公告）日：2013-11-21

  The present invention relates to benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

  本发明涉及苯并噻吩磺胺类化合物以及与葡萄糖激酶调控蛋白相互作用的其他化合物。此外，本发明涉及使用这些化合物或其药学上可接受的盐治疗2型糖尿病和其他涉及葡萄糖激酶调控蛋白的疾病和/或症状的方法，以及含有这些化合物或其药学上可接受的盐的药物组合物。
• Amino acid derivatives and their use as thrombin inhibitors
  申请人：AstraZeneca AB

  公开号：US06255301B1

  公开（公告）日：2001-07-03

  There is provided compounds of formula I, wherein R1, R2, R3, Rx, Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required as in thrombosis or as anticoagulants.

  提供了式I的化合物，其中R1、R2、R3、Rx、Y、n和B具有描述中给出的含义，这些化合物可作为类胰蛋白酶竞争性抑制剂，如凝血酶，特别适用于需要抑制凝血酶的情况，如血栓形成或抗凝剂治疗。
• New amino acid derivatives and their use as thrombin inhibitors
  申请人：AstraZeneca AB

  公开号：US20020019371A1

  公开（公告）日：2002-02-14

  There is provided compounds of formula I, 1 wherein R 1 , R 2 , R 3 , R x , Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

  提供了公式I,1的化合物，其中R1、R2、R3、Rx、Y、n和B的含义在描述中给出，这些化合物可用作类似胰蛋白酶的蛋白酶的竞争性抑制剂，如凝血酶，特别用于治疗需要抑制凝血酶的情况（如血栓形成）或作为抗凝剂。
• (Pyrazol-3-yl)-1,3,4-thiadiazol-2-amine and (pyrazol-3-yl)-1,3,4-thiazol-2-amine compounds
  申请人：Ballell Pages Lluis

  公开号：US08524750B2

  公开（公告）日：2013-09-03

  A compound of Formula (I) wherein: either X is N and Y is CR5 or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and Me; R2 is selected from H, OH, OMe and Me; each R3 is independently selected from C1-3alkyl, F, Cl, Br, CF3 and NH2; R4 is selected from Me, CF3, NO2 and CHF2; R5 is selected from H, Me and CHF2; R6 is selected from H and Me; and p is 0-3, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

  提供一种化合物，其化学式为（I），其中：X为N且Y为CR5，或者X为C且Y为S；Z从N和CH中选择；R1从H和Me中选择；R2从H，OH，OMe和Me中选择；每个R3独立地从C1-3烷基，F，Cl，Br，CF3和NH2中选择；R4从Me， ，NO2和CHF2中选择；R5从H，Me和 中选择；R6从H和Me中选择；p为0-3。还提供了含有它们的组合物，它们在治疗中的使用，例如在结核病的治疗中，并提供了制备这种化合物的方法。